New Delhi, June 14 -- Drug firm Lupin on Sunday said it has received a warning letter from the US health regulator for its Somerset facility in the US. The United States Food and Drug Administration (USFDA) had inspected the company's Somerset, New Jersey, facility from September 10, 2020, to November 5, 2020, Lupin said in a regulatory filing.

"The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility," it added.

Shares of Lupin Limited were trading more than 3% lower at Rs.1,191.9 per share on the BSE in Monday's early deals.

Lupin is committed to addressing the concerns raised by the USFDA and will work with the FDA and the NewJersey d...